Chairman Sir Nigel Rudd said re-registering as a private company is necessary to provide Destiny Pharma with a realistic chance of securing the capital required to progress XF-73 Nasal through clinical trials, without which “liquidation of the company is the most likely alternative.”

Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.